Social work supervision and discrimination

This article outlines a ‘mutual inquiry’ based approach to supervision using techniques,  concepts and insights drawn from social work supervision experience, a current Ph.D. institutional ethnographic research project and intersectionality. Good supervision of social work students and staff can progress efforts towards identifying and combatting discrimination, important steps towards a more socially just society. Reducing  discrimination also improves the quality of service provision with clients, often members  of the most marginalised groups in the community. Supervision to reduce discrimination needs to be shaped by humility rather than the more popular goal of competence. Humility is fostered when a supervisor and supervisee consider their work together from the standpoints of clients, and purposefully contemplate their complicities in the creation  and maintenance of discriminatory practices. This supervision approach aims to create the  vision, and ability, to challenge discriminatory policies and practices as they are normalised  and inflect at individual, supervision, organisational and societal levels.

Mitomycin C: a promising agent for the treatment of canine corneal scarring

Objective  To evaluate the safety and efficacy of mitomycin C (MMC) in prevention of canine corneal scarring.

Methods  With an in vitro approach using healthy canine corneas, cultures of primary canine corneal fibroblasts or myofibroblasts were generated. Primary canine corneal fibroblasts were obtained by growing corneal buttons in minimal essential medium supplemented with 10% fetal bovine serum. Canine corneal myofibroblasts were produced by growing cultures in serum-free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue assay and phase-contrast microscopy were used to evaluate the toxicity of three doses of MMC (0.002%, 0.02% and 0.04%). Real-time PCR, immunoblot, and immunocytochemistry techniques were used to determine MMC efficacy to inhibit markers of canine corneal scarring.

Results  A single 2-min treatment of 0.02% or less MMC did not alter canine corneal fibroblast or keratocyte phenotype, viability, or growth. The 0.02% dose substantially reduced myofibroblast formation (up to 67%; P < 0.001), as measured by the change in RNA and protein expression of fibrosis biomarkers (α-smooth muscle actin and F-actin).

Conclusion  This in vitro study suggests that a single 2-min 0.02% MMC treatment to the canine corneal keratocytes is safe and may be useful in decreasing canine corneal fibrous metaplasia. In vivo studies are warranted.